The fund targets a broad spectrum of healthcare sectors, including digital health, diagnostics, medical devices, R&D tools, and biopharma, with a focus on achieving positive patient outcomes, irrespective of the technology employed. Dr. Christoph Massner, Principal at Earlybird Health, says, “Eagle Eye will soon be the driver of a more effective, efficient, and inclusive deal sourcing and due diligence process for our investment teams. We are confident these efforts will yield positive outcomes for patients worldwide.” Founded in 1997, Earlybird is a VC firm that claims to invest across all phases of technology company development and growth. • Digital East Fund: Concentrated on early-stage ICT investment opportunities in Eastern Europe and Turkey, making it a leading tech VC in that region. • Earlybird-X: Backs deep tech innovation, including robotics, AI, and mobility, at the earliest stages by leveraging a network of leading European universities.